Collaboration aims to create the first-ever sublingual alprazolam powder, addressing the need for faster-acting anxiety medication. Phase 1 clinical trial of the patent-pending, rapid-onset ...
VANCOUVER, BC / ACCESS Newswire / March 24, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results